EGFR and non-small cell lung carcinoma: The active EGFR mutations in NSCLC patients exhibit Progression-Free Survival (PFS) to be longer and Objective Remission Rate (ORR) would be better by using EGFR Tyrosine Kinase Inhibitors (TKI) therapy, it also improves life quality, and decrease the side effects related to the treatment when compared with chemotherapy receiving patients (Yatabe et al., 2015).